 |
|
|
| |
Dolutegravir- versus an efavirenz 400mg-based
regimen for the initial treatment of HIV-infected
patients in Cameroon: 48-week efficacy results of
the NAMSAL ANRS 12313 trial
|
| |
| |
Reported by Jules Levin
Glasgow Oct 27-31 2018
Amandine Cournil, Charles Kouanfack, Sabrina Eymard-Duvernay, Serra Lem, Mireille Mpoudi-Ngole, Pierrette Omgba, Serge Tchokonte, Ginette Edoul Mbesse, Eitel Mpoudi-Ngole, Alexandra Calmy, Eric Delaporte, for the NAMSAL study group
Low-Dose (400-mg) Efavirenz vs Standard 600-mg Dose Studied, Found Non-Inferior Low-Dose (400-mg) Efavirenz Not Inferior to Standard 600-mg Dose
Population PK-PD Analysis of 400 mg vs. 600 mg Efavirenz Once Daily in Treatment-Naïve HIV Patients at 48 Weeks: Results of the ENCORE1 Study
Efavirenz Dose and Genotype Do Not Affect 48-Week Response in Low/Standard-Dose Trial - written by Mark Mascolini - (05/20/14)
Dolutegravir Superior to Efavirenz at 144 Weeks in SINGLE Trial
Dolutegravir plus Abacavir-Lamivudine vs Efavirenz/TDF/FTC Once Daily for the Treatment of HIV-1 Infection
48 Week Bone Marker Changes in Dolutegravir (DTG; GSK1349572) Plus Abacavir/Lamivudine (ABC/3TC) vs Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): The SINGLE Trial - (09/13/13)
|
| |
|
|
|
|
|
